Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFA-2000
- Development stage
- Preclinical
- Lead developer
- AfaSci
- Modality
- Small Molecules
01
Overview
AFA-2000 is a preclinical small molecule drug candidate being developed by AfaSci, Inc. It functions as a modulator of G protein-coupled inwardly rectifying potassium (GIRK) channels. By directly activating these channels, the compound aims to reduce neuronal excitability, offering a potential therapeutic approach for chronic and neuropathic pain as well as sleep disorders such as insomnia. Research indicates that GIRK activation can promote non-rapid eye movement (NREM) sleep. The drug is currently in the lead optimization stage of development.
Beyond the preview
Go deeper on AFA-2000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFA-2000.